Mutation in RAP1 is a rare event in myelodysplastic syndromes [5]

Leukemia

Volumn 19, Issue 9, 2005, Pages 1678-1680

  Gyan, E ^a   Frew, M ^b   Bowen, D ^b   Beldjord, C ^c   Preudhomme, C ^d   Lacombe, C ^a   Mayeux, P ^a   Dreyfus, F ^a,c   Porteu, F ^a   Fontenay, M ^a  

^a INSTITUT COCHIN   (France)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c AP HP ^*  (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RAP1 PROTEIN; RAS PROTEIN; RAP PROTEIN; RAP1A PROTEIN, HUMAN; RAP1B PROTEIN, HUMAN;

AMINO ACID SUBSTITUTION; BONE MARROW BIOPSY; CELL ISOLATION; CONTROLLED STUDY; DENATURING GRADIENT GEL ELECTROPHORESIS; DNA EXTRACTION; FEMALE; GENE MUTATION; GENETIC SCREENING; HETERODUPLEX ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; KARYOTYPING; LETTER; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MYELODYSPLASTIC SYNDROME; POINT MUTATION; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; COMPARATIVE STUDY; GENETICS; NUCLEOTIDE SEQUENCE;

DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES; POINT MUTATION; RAP GTP-BINDING PROTEINS; RAP1 GTP-BINDING PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 26944438049     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2403882     Document Type: Letter

References (8)

1. Steensma DP, Tefferi A. The myelodysplastic syndrome(S): A perspective and review highlighting current controversies. Leuk Res 2003; 27: 95-120.
2. Bowen DT, Frew ME, Hills R, Gale RE, Wheatley K, Groves MJ et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients <60 yrs. Blood 2005, 16 June [E-pub ahead of print].
3. Paquette RL, Landaw EM, Pierre RV, Kahan J, Lubbert M, Lazcano O et al. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 1993; 82: 590-599.
4. Hariharan IK. Ras and Rap: Are former enemies now friends? Dev Cell 2005; 8: 303-304.
5. Garcia J, de Gunzburg J, Eychene A, Gisselbrecht S, Porteu F. Thrombopoietin-mediated sustained activation of extracellular signal-regulated kinase in UT7-Mpl cells requires both Ras-Raf-1- and Rap1-B-Raf-dependent pathways. Mol Cell Biol 2001; 21: 2659-2670.
6. Ishida D, Kometani K, Yang H, Kakugawa K, Masuda K, Iwai K et al. Myeloproliferative stem cell disorders by deregulated Rap1 activation in SPA-1-deficient mice. Cancer Cell 2003; 4: 55-65.
7. Vanvooren V, Allgeier A, Nguyen M, Massart C, Parma J, Dumont JE et al. Mutation analysis of the Epac-Rap1 signaling pathway in cold thyroid follicular adenomas. Eur J Endocrinol 2001; 144: 605-610.
8. Scheffzek K, Ahmadian MR, Kabsch W, Wiesmuller L, Lautwein A, Schmitz F et al. The Ras-RasGAP complex: Structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 1997: 277: 333-338.